This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Biotech's Longer Convalescence

Survey Says

I conducted an informal and unscientific sentiment poll of more than two dozen biotech money managers, traders and buy-side research analysts. A clear majority of respondents agree the biotech sector is in a deep hole and will be unable to finish 2004 up for the year. (Certainly the sector has little chance of matching or besting its performance in 2003 when the Amex Biotech Index closed 2003 at 490, up 45%, and the Nasdaq Biotech Index closed 2003 at 724, up 47%.)

But these biotech mavens are more optimistic when it comes to forecasting the performance of the sector from current levels. A clear majority believes the sector will finish the year higher than Monday's close. It's important to note, however, that many of those same respondents feel things could get worse before they get better -- which means the sector may not have put in its bottom just yet.

Of course, moving biotech stocks higher will require getting a wider circle of investors -- and not just these dozen-plus specialists -- to start buying. Wayne Rothbaum, a hedge fund manager with Quogue Capital, doesn't necessarily see that happening any time soon.

"What props up the biotech group is when momentum guys, the big aggressive growth funds and market-timers want to get into the sector. But now, these guys have been selling stocks as fast, or faster, than they were buying them," he said. "And price deflation is worse now because there is no buying support."

Biotechs also will have to overcome the impression that valuations are still not cheap, by historical standards. While companies generally met or exceeded earnings expectations for the second quarter, they did not significantly raise EPS forecasts. And in a bear market, especially one accompanied by the threat of rising interest rates, valuation multiples are typically compressed.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,293.48 -93.73 -0.54%
S&P 500 2,018.48 -11.07 -0.55%
NASDAQ 4,675.21 -6.2870 -0.13%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs